US
(888) 440-0954
Home  |   Press  |  MedGenome’s study suggests a personalized cancer vaccine approach to treat Lynch Syndrome

MedGenome’s study suggests a personalized cancer vaccine approach to treat Lynch Syndrome

The published study examines the feasibility of treating Lynch syndrome using a personalized cancer vaccine approach by identifying potential immunogenic tumor specific alterations.

Lynch syndrome is a hereditary cancer arising from loss of function mutations in DNA mismatch repair genes, such as MLH1, MSH2, MSH3, MSH6, PMS2, and EPCAM. “Over 1 million Americans are affected by Lynch syndrome according to the Cancer Moonshot Blue Ribbon Panel, wherein only 5% are aware of this” said Prof Henry T. Lynch whose groundbreaking research in 1960s led to the discovery of cancer family syndrome or hereditary nonpolyposis colorectal cancer (HNPCC) also referred to as Lynch syndrome.

Considering genomic research?

We’re at your service

*
 
*
*